Antiplatelet therapy and atherosclerotic events. Risks and patients' values need to be included in decision about aspirin for prevention of coronary heart disease
Pignone, M.; Mulrow, C.
Bmj 324(7342): 917
2002
ISSN/ISBN: 0959-8138 PMID: 11951911 Document Number: 543325
Document emailed within 1 workday
Related Documents
Kawecka-Jaszczowa, K.; Szczeklik, J.; Mysik, M.; Miłkowski, A. 1976: Blood pressure values in men included in prevention of coronary heart disease Przeglad Lekarski 33(6): 623-628Muslimova, E.F.; Afanasiev, S.A.; Rebrova, T.Yu.; Sergienko, T.N.; Repin, A.N. 2017: Association of ITGB3, P2RY12, and CYP2C19 gene polymorphisms with platelet functional activity in patients with coronary heart disease during dual antiplatelet therapy Terapevticheskii Arkhiv 89(5): 74-78
Long Term Intervention With Pravastatin, I.Ischaemic Disease Study Group 1998: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels New England Journal of Medicine 339(19): 1349-1357
Mutter, J.; Grandy, R.; Hulkower, S.; Stigleman, S. 2018: Clinical Inquiries: What are the benefits and risks of daily low-dose aspirin for primary prevention of CV events? Journal of Family Practice 67(4): 247-248
Lindbloom, E.J.; Eaton, L.J. 2002: Cost effectiveness of aspirin vs clopidogrel for secondary prevention of coronary heart disease Journal of Family Practice 51(9): 789
Degrauwe, S.; Iglesias, J.F. 2016: Dual antiplatelet therapy for treatment and secondary prevention of coronary artery disease: indications, modalities and duration Revue Medicale Suisse 12(520): 1022-6 1028-34
Hostetter, J.C.; Bhatt, D.L. 2003: The expanding role of antiplatelet agents in coronary artery disease. a current review of aspirin, glycoprotein IIb/IIIa inhibitors, and the thienopyridines Minerva Cardioangiologica 51(5): 531-546
Jain, A.; Mehrotra, T.N.; Goel, V.K.; Mehrotra, M.L.; Raka, M.S. 1982: Effect of aspirin on plasma fibrinolytic activity in patients of coronary heart disease Journal of the Association of Physicians of India 30(7): 441-443
Wang, R.M. 1994: Nursing observation of arrhythmia in patients with coronary atherosclerotic heart disease during nocturnal sleep Zhonghua Hu Li Za Zhi 29(12): 729-731
Maseri, A.; Chierchia, S.; L'Abbate, A. 1980: Pathogenetic mechanisms underlying the clinical events associated with atherosclerotic heart disease Circulation 62(6 Part 2): V3-V13
Gifford, R.W. 1983: Antihypertensive therapy and survival of patients with atherosclerotic heart disease Mayo Clinic Proceedings 58(4): 275-276
Gaciong, Z. 2006: Clopidogrel and aspirin versus aspirin alone in prevention of atherothrombotic events. The results of CHARISMA study Kardiologia Polska 64(5): 548
Ning, X.-h.; Xiang, X.-p.; Lu, N.; Zhang, Y.-x.; Wang, W.-j.; Liu, Y.; Zhou, Z. 2008: Relation of risk factors to coronary artery stenosis severity in coronary atherosclerotic heart disease Zhonghua Yi Xue Za Zhi 88(18): 1267-1269
1980: Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group Circulation 62(3): 449-461
De Caterina, R. 2003: Low-dose aspirin in the primary prevention of cardiovascular disease: how to balance the benefits and the risks Italian Heart Journal: Official Journal of the Italian Federation of Cardiology 4(4): 228-231
Liu, H.; Chen, Z.; Gao, R. 1995: Effects of low dose aspirin on platelet function and prostaglandins metabolism in systemic and coronary circulation in patients with ischemia heart disease Zhonghua Nei Ke Za Zhi 34(9): 595-598
Guo, Y.F. 2019: Effects of aspirin on primary prevention of cardiovascular events in patients with hypertension Zhonghua Nei Ke Za Zhi 58(4): 249-251
Jenni, D.; Osterwalder, R.; Osswald, S.; Buser, P.; Pfisterer, M. 2001: Are we treating coronary heart disease and heart failure appropriately in the clinic and ambulatory care? Secondary prevention and drug therapy 1998 Praxis 90(41): 1759-1765
Arntz, H.R.; Wunderlich, W.; Schnitzer, L.; Stern, R.; Fischer, F.; Agrawal, R.; Linderer, T.; Schultheiss, H.P. 1999: Short- and long-term effects of intensified versus conventional antilipidemic therapy in patients with coronary heart disease. Results from the Lipid-Coronary Artery Disease (L-CAD) Study Zeitschrift für Kardiologie 88(8): 582-590
Groos, M. 1993: Pathogenesis of coronary heart disease and acute coronary events Medizinische Monatsschrift für Pharmazeuten 16(5): 142-145